In this trial, the investigators aim to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) and its impact on airway inflammation in former and current smokers with COPD diagnosed at least one year and aged between 40 and 70 years. Here, IL33 is linked to chronic obstructive pulmonary disease.